Gilead Sciences (GILD) Minority Interest (2009 - 2026)
Gilead Sciences' (GILD) quarterly Minority Interest came in at -$84.0 million in Q1 2026, little changed YoY from -$84.0 million in Q1 2025, and little changed on a QoQ basis from -$84.0 million in Q4 2025.
Gilead Sciences (GILD) Minority Interest (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Minority Interest data on file, last reported at -$84.0 million in Q1 2026.
- Quarterly Minority Interest changed 0.0% year-over-year to -$84.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.0 million (changed 0.0% YoY) and the FY2025 annual result came in at -$84.0 million, changed 0.0% from the prior year.
- Minority Interest was little changed at -$84.0 million in Q1 2026, from -$84.0 million in the prior quarter.
- In the past five years, Minority Interest ranged from a high of -$12.0 million in Q1 2022 to a low of -$84.0 million in Q4 2023.
- A 5-year average of -$66.0 million and a median of -$84.0 million in 2023 frame the typical range for Minority Interest.
- Annual changes were most pronounced in 2022 — Minority Interest plunged 2500.0% — and 2024, when it changed 0.0%.
- Tracing GILD's Minority Interest over 5 years: stood at -$31.0 million in 2022, then tumbled by 170.97% to -$84.0 million in 2023, then changed by 0.0% to -$84.0 million in 2024, then changed by 0.0% to -$84.0 million in 2025, then changed by 0.0% to -$84.0 million in 2026.
- The last three Minority Interest figures came in at -$84.0 million (Q1 2026), -$84.0 million (Q4 2025), and -$84.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.62 Bn | 633.86 Bn | 17.26 Bn |
| 2 | AbbVie | 471.49 Bn | 464.92 Bn | 12.70 Bn |
| 3 | Merck | 380.76 Bn | 373.62 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.50 Bn | 295.81 Bn | 11.24 Bn |
| 5 | Astrazeneca | 258.69 Bn | 253.79 Bn | 12.86 Bn |
| 6 | Amgen | 237.83 Bn | 223.84 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.09 Bn | 179.91 Bn | 6.22 Bn |
| 8 | Pfizer | 161.60 Bn | 149.90 Bn | 10.94 Bn |
| 9 | Gsk | 105.97 Bn | 101.81 Bn | 8.24 Bn |
| 10 | Sanofi | 55.33 Bn | 47.95 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.00 Mn |
| Mar 31, 2026 | -84.00 Mn |
| Dec 31, 2025 | -84.00 Mn |
| Sep 30, 2025 | -84.00 Mn |
| Jun 30, 2025 | -84.00 Mn |
| Mar 31, 2025 | -84.00 Mn |
| Dec 31, 2024 | -84.00 Mn |
| Sep 30, 2024 | -84.00 Mn |
| Jun 30, 2024 | -84.00 Mn |
| Mar 31, 2024 | -84.00 Mn |
| Dec 31, 2023 | -84.00 Mn |
| Sep 30, 2023 | -72.00 Mn |
| Jun 30, 2023 | -64.00 Mn |
| Mar 31, 2023 | -58.00 Mn |
| Dec 31, 2022 | -31.00 Mn |
| Sep 30, 2022 | -24.00 Mn |
| Jun 30, 2022 | -21.00 Mn |
| Mar 31, 2022 | -12.00 Mn |
| Dec 31, 2021 | -5.00 Mn |
| Sep 30, 2021 | 1.00 Mn |